Lipid nanoparticles (LNP) are a commonly used delivery vehicle that can facilitate transfection of encapsulated mRNA in cells. After endosomal escape, mRNA is released and translated into the protein of interest.

CATUG’s high quality LNP products are developed using the approved Moderna COVID-vaccine formulation consisting of SM-102 ionizable lipid, DSPC, PEG-DMG-2000, and cholesterol.

Our mRNA-LNP product offerings currently focus on reporter genes such as firefly luciferase, mCherry, and EGFP; however, we also take custom requests for your specific mRNA and LNP formulation of interest.

Our experts can also perform high throughput screening of our library of hundreds of LNP formulations and validate its performance for your intended application in vivo​